Pharma News

Zai Lab presented promising preclinical data on ZL-1503, an IL-13 and IL-31Ralpha bispecific antibody, for treating atopic dermatitis at IMMUNOLOGY2026.

FDA grants fast-track status to Aligos Therapeutics' pevifoscorvir sodium for chronic hepatitis B. Phase 2 trial shows promising interim data.

HiberCell presents preclinical data at AACR 2026 showing HC-7366 combined with VEGFR-TKIs enhances antitumor activity in ccRCC models.

A new nasal spray developed by Texas A&M researchers reverses age-related brain inflammation and restores memory in preclinical models.

Eli Lilly and Eisai defend their Alzheimer’s drugs, Kisunla and Leqembi, after a Cochrane review questions the clinical efficacy of anti-amyloid therapies.

Filana Therapeutics publishes preclinical data in Epilepsia showing simufilam attenuates seizure progression in severe TSC-related epilepsy mouse models.

Small and midsize biotech firms face tough choices as new 100% tariffs loom. Will they strike MFN pricing deals or risk devastating financial impacts?

FDA approves Travere Therapeutics' sparsentan (Filspari) as the first drug for focal segmental glomerulosclerosis (FSGS), a rare kidney scarring disease.

Rice University researchers built a custom AI to uncover hidden behavior patterns in self-organizing bacteria, revealing early biological transition signs.

Annovis Bio partners with NeuroRPM to use an FDA-cleared AI platform for tracking Parkinson's symptoms in the ANVS-25002 study evaluating buntanetap.

Hoth Therapeutics announces positive HT-VA study data showing GDNF reprograms liver fat metabolism at the genetic level, offering a novel MAFLD treatment.

GSK withdraws its application for Wellcovorin (leucovorin), recently touted by the FDA and Trump administration as a potential autism and CFD treatment.